Recent studies indicated that sensitive parasites could increase in frequency in a population when drugs are removed, suggesting that the life span of affordable antimalarial drugs could be expanded. We studied 97 samples from Bolivar State, Venezuela, an area where sulfadoxine-pyrimethamine (SP) has not been used for 8 years due to its ineffectiveness. We characterized point mutations in two genes that have been implicated in resistance to SP, dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps). We also assayed neutral microsatellite markers around the dhfr (chromosome 4) and dhps (chromosome 8) genes and on chromosomes 2 and 3 to track the origin and spread of resistant alleles. We found that drug-resistant SP mutants are fixed in the population. Two genotypes were present in the samples, dhfr(50R/51I/108N) dhps(437G/540E/581G) (90.7%) and dhfr(51I/108N) dhps(437G/581G) (9.3%). We show a single microsatellite haplotype for all of the dhfr and dhps alleles, and the alleles at the microsatellite loci are different from those present in Africa. Thus, in these samples from Venezuela, there is a single origin for both dhfr and dhps SP-resistant alleles, and these alleles originated independently of those characterized from Africa. Furthermore, this is the first report of a "hitchhiking effect" on the genetic variation around dhps due to selection by SP using an extensive set of microsatellite markers. Our results indicate that, in areas where there is limited gene flow, the fixation of drug-resistant parasites in the population is stable, even after drug selection is relaxed.The emergence of drug-resistant Plasmodium falciparum is a serious public health problem in many countries where malaria is endemic (7, 28). Sulfadoxine-pyrimethamine (SP) is an antifolate drug commonly used to treat P. falciparum infections because of its ease of administration, affordability, and efficacy. Unfortunately, resistance to SP has been documented in many parts of the world, compromising the use of this drug for treating uncomplicated P. falciparum malaria.SP acts as an inhibitor of the P. falciparum folic acid pathway, and point mutations in the genes encoding dihydrofolate reductase (dhfr) and dihydropteroate synthetase (dhps) have been implicated in SP resistance (9). The dhfr(S108N) point mutation and additional mutations at codons 50, 51, 59, and 164 act synergistically to increase resistance to pyrimethamine (4, 21). Similarly, mutations at dhps codons 436, 437, 540, 581, and 613 act synergistically to increase the level of resistance to sulfadoxine (7).Recent studies following the frequency of chloroquine-resistant parasites over time showed that sensitive parasites could increase in frequency soon after the drug pressure on the parasite population was decreased (13). These results suggest that, with appro-